Skip to Content

EADV24: Semaglutide Shows Promising Outcomes for Obese Patients with Hidradenitis Suppurativa

A study presented Wednesday, 25 September 2024, at the EADV Congress 2024 in Amsterdam highlights the significant potential of semaglutide in treating hidradenitis suppurativa (HS) in obese patients.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top